Peter Lawson
Stock Analyst at Barclays
(2.06)
# 2,948
Out of 5,149 analysts
102
Total ratings
42.7%
Success rate
-8.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Overweight | $394 → $405 | $297.04 | +36.35% | 3 | Feb 27, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $21.40 | +2.80% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $98.07 | +2.99% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $34.31 | +16.58% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $12.50 | +100.00% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $7.17 | -58.16% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $40.74 | -1.82% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.89 | +58.73% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.37 | +45.99% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $9.13 | +9.53% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $3.75 | +6.81% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $12.02 | -50.08% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $52 | $32.36 | +60.69% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $8.50 | +29.41% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $13.36 | +19.76% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $5.50 | +172.73% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $22.43 | -37.58% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.33 | +125.56% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.04 | +189.86% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.44 | +177.78% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $100.49 | -40.29% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $9.85 | +72.59% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $15.81 | +96.08% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $11.50 | +13.04% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $2.63 | +90.11% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $4.81 | -27.23% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $129.56 | +181.72% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $28.48 | +61.52% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $68.11 | +560.70% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.04 | +2,105.88% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $58.06 | -22.49% | 2 | Jan 23, 2018 |
BeOne Medicines AG
Feb 27, 2026
Maintains: Overweight
Price Target: $394 → $405
Current: $297.04
Upside: +36.35%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $21.40
Upside: +2.80%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $98.07
Upside: +2.99%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $34.31
Upside: +16.58%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $12.50
Upside: +100.00%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $7.17
Upside: -58.16%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $40.74
Upside: -1.82%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.89
Upside: +58.73%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.37
Upside: +45.99%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $9.13
Upside: +9.53%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $3.75
Upside: +6.81%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $12.02
Upside: -50.08%
May 7, 2025
Maintains: Overweight
Price Target: $66 → $52
Current: $32.36
Upside: +60.69%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $8.50
Upside: +29.41%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $13.36
Upside: +19.76%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $5.50
Upside: +172.73%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $22.43
Upside: -37.58%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.33
Upside: +125.56%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.04
Upside: +189.86%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.44
Upside: +177.78%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $100.49
Upside: -40.29%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $9.85
Upside: +72.59%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $15.81
Upside: +96.08%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $11.50
Upside: +13.04%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.63
Upside: +90.11%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $4.81
Upside: -27.23%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $129.56
Upside: +181.72%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $28.48
Upside: +61.52%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $68.11
Upside: +560.70%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.04
Upside: +2,105.88%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $58.06
Upside: -22.49%